Jacob Soumerai, MD
Enriched profileClinical Investigator in Lymphoma, Massachusetts General Hospital; Assistant Professor of Medicine, Harvard Medical School · Massachusetts General Hospital Cancer Center
Jacob Soumerai is Clinical Investigator in Lymphoma, Massachusetts General Hospital; Assistant Professor of Medicine, Harvard Medical School at Massachusetts General Hospital Cancer Center. OpenAlex indexes 190 publications with 4,826 citations (h-index 27); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Jacob Soumerai, MD, is Clinical Investigator in Lymphoma, Massachusetts General Hospital at Massachusetts General Hospital Cancer Center. The public record shows 190 publications with 4,826 citations (h-index 27), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 13 companies, 1 NIH-funded awards (2023–2026).
- Most recent indexed publication: 2026 · Blood
- Top research focus: Lymphoma Diagnosis and Treatment
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 24 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 64.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Sponsor: Massachusetts General Hospital
- Biomarker for Infection Risk in CLL and MM
Sponsor: Massachusetts General Hospital
- Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Sponsor: Jacob Soumerai, MD
Industry payments
Updated 16 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Grifols Shared Services North America, Inc.Program year20251 payment
- BeOne Medicines USA, Inc.Program year20257 payments
- F. Hoffmann-La Roche AGProgram year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.1%Kinase inhibitor39.1%Brukinsa82%Jaypirca18%Part D<11 patientsMetabolism & gastrointestinal
25%Corticosteroid15.4%Prednisone100%Part D≥15 patientsSerotonin-3 Receptor Antagonist9.6%Ondansetron Hcl100%Part D≥12 patientsAnti-infectives
12.8%Short-acting sulfonamides12.8%Sulfamethoxazole-Trimethoprim100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- Predictive markers for personalized therapy in chronic lymphocytic leukemia
Massachusetts General Hospital
FY2026$285,931K08CA270202 - Predictive markers for personalized therapy in chronic lymphocytic leukemia
Massachusetts General Hospital
FY2025$285,931K08CA270202 - Predictive markers for personalized therapy in chronic lymphocytic leukemia
Massachusetts General Hospital
FY2024$285,931K08CA270202
Congress activity
Updated 16 Oct 2026
57 congress contributions (2006–2026) across ASCO, ASH per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.
Blood advances
Clinical Trial2026 - Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis.
Leukemia & lymphoma
Article2026
Most-cited works
by citation count (OpenAlex)- 01The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patientsArticle920 citations2020
- 02
- 03
- 04Atorvastatin for Anthracycline-Associated Cardiac DysfunctionArticle214 citations2023
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jacob-soumerai-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
bloodcancerunited.org/taxonomy/term/72806
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerunited.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
- Board certified in Hematology
American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗ - Board certified in Medical Oncology
American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nccn.digitellinc.com ↗
- Mass General Brigham Cancer Institute
Hagler Center for Lymphoma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Noopur Raje, MD
Massachusetts General Hospital Cancer Center
Andrew Yee, MD
Massachusetts General Hospital Cancer Center
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Wyndham Wilson, MD
National Cancer Institute (NCI)
Julie Vose, MD
University of Nebraska Medical Center